MedTrace Logo

Personalized Prediction of Tolerance and Immunogenicity in Hemophilia

NCT01626105 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2012-07-26

No results posted yet for this study

Summary

This study is designed to accurately identify the pharmacogenetic determinants of risk of Factor VIII (FVIII) inhibitor development by focusing on only a select group of Hemophilia A (HA) patients who have: (i) received a recombinant FVIII therapeutic product containing the same primary amino acid sequence since their original diagnosis; (ii) verifiable FVIII infusion histories; and (iii) been tested regularly for FVIII inhibitor development.

Conditions

Sponsors & Collaborators

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • Victor J Marder, M.D.

    lead OTHER

Principal Investigators

  • Victor J. Marder, M.D. · The Los Angeles Orthopaedic Hospital and The David Geffen School of Medicine at UCLA

Eligibility

Min Age
2 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-04-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01626105 on ClinicalTrials.gov